Your browser doesn't support javascript.
loading
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma.
Ascierto, Paolo Antonio; Del Vecchio, Michele; Mackiewicz, Andrzej; Robert, Caroline; Chiarion-Sileni, Vanna; Arance, Ana; Lebbé, Céleste; Svane, Inge Marie; McNeil, Catriona; Rutkowski, Piotr; Loquai, Carmen; Mortier, Laurent; Hamid, Omid; Bastholt, Lars; Dreno, Brigitte; Schadendorf, Dirk; Garbe, Claus; Nyakas, Marta; Grob, Jean-Jacques; Thomas, Luc; Liszkay, Gabriella; Smylie, Michael; Hoeller, Christoph; Ferraresi, Virginia; Grange, Florent; Gutzmer, Ralf; Pikiel, Joanna; Hosein, Fareeda; Simsek, Burcin; Maio, Michele.
Afiliación
  • Ascierto PA; Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy paolo.ascierto@gmail.com.
  • Del Vecchio M; Unit of Melanoma Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy.
  • Mackiewicz A; Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Center, Poznan Medical University, Poznan, Poland.
  • Robert C; Department of Medicine, Dermatology Service, Gustave Roussy, Villejuif and Paris-Sud-University, Le Kremlin-Bicêtre, France.
  • Chiarion-Sileni V; Melanoma Oncology Unit, Istituto Oncologico Veneto-IRCCS, Padova, Italy.
  • Arance A; Hospital Clinic and Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Lebbé C; Université de Paris, INSERM, Dermatology and CIC, Saint Louis Hospital, Paris, France.
  • Svane IM; Center for Cancer Immune Therapy, Herlev Hospital, Herlev, Denmark.
  • McNeil C; Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
  • Rutkowski P; Chris O'Brien Lifehouse and Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
  • Loquai C; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland.
  • Mortier L; Department of Dermatology, University Medical Center, Mainz, Germany.
  • Hamid O; Clinique de Dermatologie, Unité d'Onco-Dermatologie, INSERM U1189, Centre Hospitalier Régional Universitaire de Lille, Hôpital Claude Huriez, Lille, France.
  • Bastholt L; Melanoma Center, The Angeles Clinic and Research Institute, Los Angeles, California, USA.
  • Dreno B; Department of Oncology, Odense University Hospital, Odense, Denmark.
  • Schadendorf D; Department of Oncodermatology, University Hospital Centre Nantes, Nantes, Pays de la Loire, France.
  • Garbe C; Department of Dermatology, University Hospital Essen, Essen, Nordrhein-Westfalen, Germany.
  • Nyakas M; Department of Dermatology, German Cancer Consortium, Heidelberg, Germany.
  • Grob JJ; Department of Dermatology, Eberhard Karls Universitat Tübingen, Tübingen, Baden-Württemberg, Germany.
  • Thomas L; Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Liszkay G; Dermatology and Skin Cancers Department, Aix-Marseille University, APHM, Marseille, France.
  • Smylie M; Department of Dermatology, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.
  • Hoeller C; Department of Oncodermatology, National Institute of Oncology, Budapest, Hungary.
  • Ferraresi V; Department of Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada.
  • Grange F; Division of General Dermatology and Dermato-Oncology, Medical University of Vienna, Vienna, Austria.
  • Gutzmer R; Unit of Medical Oncology, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
  • Pikiel J; Department of Dermatology, University Hospital Centre Reims, Reims, Champagne-Ardenne, France.
  • Hosein F; Operative Dermatology and Dermato-Oncology, Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany.
  • Simsek B; Department of Oncology, Wojewodzkie Centrum Oncologii, Gdansk, Poland.
  • Maio M; Oncology Clinical Development, Bristol-Myers Squibb Co, Princeton, New Jersey, USA.
J Immunother Cancer ; 8(1)2020 06.
Article en En | MEDLINE | ID: mdl-32503946
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Ipilimumab / Inhibidores de Puntos de Control Inmunológico / Melanoma Tipo de estudio: Clinical_trials / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Humans / Middle aged Idioma: En Revista: J Immunother Cancer Año: 2020 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Ipilimumab / Inhibidores de Puntos de Control Inmunológico / Melanoma Tipo de estudio: Clinical_trials / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Humans / Middle aged Idioma: En Revista: J Immunother Cancer Año: 2020 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido